Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.

ABSTRACT:

Background

CDK12 genomic alterations occur in several tumor types, but little is known about their oncogenic role and clinical significance.

Objective

To describe the landscape of CDK12 alterations across solid cancers and the clinical features of CDK12-altered prostate cancer.

Design, setting, and participants

A single-center retrospective study of 26743 patients across 25 solid tumor types who underwent tumor sequencing was performed. Clinicopathologic features and outcomes were assessed in prostate cancer.

Outcome measurements and statistical analysis

CDK12 alterations and their association with genomic characteristics are described. For prostate cancer patients, overall survival and time to castration resistance were assessed using univariable and multivari

SUBMITTER: Nguyen B 

PROVIDER: S-EPMC7572747 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature